Kiniksa Pharmaceuticals International (NASDAQ:KNSA) CAO Michael Megna Sells 4,600 Shares

Key Points

• Kiniksa CAO Michael Megna sold 4,600 shares at an average price of $80.30, generating $369,380; the transaction was conducted under a pre-arranged Rule 10b5-1 plan and reduced his direct ownership by 13.67%.
• KNSA shares traded near their 12-month high at $80.47, up $0.58, with a $6.28 billion market capitalization. The company recently met quarterly EPS expectations at $0.30 and exceeded revenue estimates with $243.6 million.
• Analyst sentiment remains positive, with eight Buy ratings and two Holds; the stock has a consensus rating of Moderate Buy and an average price target of $87.38.

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) CAO Michael Megna sold 4,600 shares of the firm's stock in a transaction dated Thursday, September 3rd. The stock was sold at an average price of $80.30, for a total transaction of $369,380.00. Following the completion of the sale, the chief accounting officer directly owned 29,062 shares of the company's stock, valued at approximately $2,333,678.60. This represents a 13.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kiniksa Pharmaceuticals International Stock Performance

Shares of KNSA traded up $0.58 on Thursday, reaching $80.47. The stock had a trading volume of 620,821 shares, compared to its average volume of 697,580. Kiniksa Pharmaceuticals International, plc has a 12-month low of $35.06 and a 12-month high of $82.94. The firm has a market capitalization of $6.28 billion, a price-to-earnings ratio of 82.96 and a beta of 0.09. The company has a 50-day simple moving average of $71.13 and a 200-day simple moving average of $56.97.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last released its earnings results on Tuesday, July 28th. The company reported $0.30 earnings per share for the quarter, hitting analysts' consensus estimates of $0.30. Kiniksa Pharmaceuticals International had a net margin of 9.59% and a return on equity of 13.65%. The firm had revenue of $243.60 million for the quarter, compared to the consensus estimate of $226.49 million. On average, analysts expect that Kiniksa Pharmaceuticals International, plc will post 1.37 EPS for the current fiscal year.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals International

A number of large investors have recently added to or reduced their stakes in KNSA. Nykredit A S purchased a new stake in Kiniksa Pharmaceuticals International during the second quarter valued at approximately $34,000. KBC Group NV acquired a new stake in Kiniksa Pharmaceuticals International during the first quarter worth about $34,000. Smartleaf Asset Management LLC purchased a new stake in Kiniksa Pharmaceuticals International during the fourth quarter worth $36,000. EverSource Wealth Advisors LLC increased its stake in shares of Kiniksa Pharmaceuticals International by 140.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company's stock valued at $25,000 after purchasing an additional 532 shares in the last quarter. Finally, Nano Cap New Millennium Growth Fund L P purchased a new position in shares of Kiniksa Pharmaceuticals International during the 4th quarter valued at approximately $41,000. 53.95% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

KNSA has been the topic of a number of research analyst reports. Wall Street Zen downgraded shares of Kiniksa Pharmaceuticals International from a "strong-buy" rating to a "buy" rating in a research report on Sunday, July 12th. Wedbush increased their price target on Kiniksa Pharmaceuticals International from $72.00 to $99.00 and gave the stock an "outperform" rating in a research note on Wednesday, July 29th. Weiss Ratings downgraded shares of Kiniksa Pharmaceuticals International from a "buy (b-)" rating to a "hold (c+)" rating in a report on Thursday, August 13th. Wells Fargo & Company boosted their price target on shares of Kiniksa Pharmaceuticals International from $57.00 to $74.00 and gave the stock an "overweight" rating in a research report on Monday, July 13th. Finally, Canaccord Genuity Group increased their price target on Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the company a "buy" rating in a report on Wednesday, July 29th. Eight investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, Kiniksa Pharmaceuticals International has a consensus rating of "Moderate Buy" and an average target price of $87.38.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company's core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company's lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still's disease and Schnitzler syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source